Bemarituzumab is under clinical development by Amgen and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bemarituzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bemarituzumab overview

Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such as gastric cancer, gastroesophageal cancer, transitional cell carcinoma, lymphoma, bladder cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, colorectal adenocarcinoma, ovarian epithelial cell carcinoma, endometrial adenocarcinoma and cervical carcinoma. The drug candidate is administered through intravenous route. It is a humanized monoclonal antibody directed against a splice form of fibroblast growth factor receptor 2 (FGFR2). It is a targeted immunotherapy for FGFR2b-overexpressing tumors and designed to recruit tumor-killing NK cells into the tumor microenvironment. The drug candidate is developed based on Potelligent CHOK1SV technology. Potelligent CHOK1SV, combines the advantages of GS Gene Expression System with the glyco-engineered technology.

It was also under development for the treatment of breast cancer.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

For a complete picture of Bemarituzumab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.